← All trials
NCT02340949
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2015
- Primary completion
- Sep 1, 2017
- Completion date
- Feb 1, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 180
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Grupo Espanol Multidisciplinario del Cancer DigestivoLead sponsor
- Universidad Complutense de MadridOverall official - principal investigator
- Universidad Autonoma de BarcelonaOverall official - principal investigator
- University of CantabriaOverall official - principal investigator
- Miguel Hernández UniversityOverall official - principal investigator
- University of BarcelonaOverall official - principal investigator
- Hospital Universitario Madrid SanchinarroOverall official - principal investigator
- Fundación Althaia ManresaOverall official - principal investigator
- University AlicanteOverall official - principal investigator
- Badalona Hospital Germans Trias i PujolOverall official - principal investigator
- Hospital de GranollersOverall official - principal investigator
- Hospital General Universitario de CastellónOverall official - principal investigator
- University of ValenciaStudy director
- Pivotal S.L.Collaborator
- University of ZaragozaOverall official - principal investigator
- Clinica Universidad de NavarraOverall official - principal investigator
- Universidad Autonoma de MadridOverall official - principal investigator
- Hospital Universitario Arnau de Vilanova de LleidaOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.